1. Home
  2. NPT vs GANX Comparison

NPT vs GANX Comparison

Compare NPT & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NPT

Texxon Holding Limited Ordinary shares

N/A

Current Price

$5.74

Market Cap

110.9M

ML Signal

N/A

Logo Gain Therapeutics Inc.

GANX

Gain Therapeutics Inc.

HOLD

Current Price

$4.07

Market Cap

117.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NPT
GANX
Founded
2011
2017
Country
China
United States
Employees
N/A
N/A
Industry
Specialty Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
110.9M
117.7M
IPO Year
2025
2021

Fundamental Metrics

Financial Performance
Metric
NPT
GANX
Price
$5.74
$4.07
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$8.00
AVG Volume (30 Days)
48.2K
1.1M
Earning Date
11-18-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$797,148,640.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
18.51
N/A
52 Week Low
$3.14
$1.41
52 Week High
$9.18
$4.34

Technical Indicators

Market Signals
Indicator
NPT
GANX
Relative Strength Index (RSI) N/A 75.70
Support Level N/A $3.94
Resistance Level N/A $4.34
Average True Range (ATR) 0.00 0.37
MACD 0.00 0.07
Stochastic Oscillator 0.00 88.10

Price Performance

Historical Comparison
NPT
GANX

About NPT Texxon Holding Limited Ordinary shares

Texxon Holding Ltd provides technology-enabled supply chain management services to customers in the plastics and chemical industries in East China. The company operates through two segments: Supply Chain Trading and Plastic Manufacturing. Its services include procurement, logistics, payments, and fulfillment for Chinese SMEs, and all revenue is generated from operations within the People's Republic of China.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.

Share on Social Networks: